I N T R O D U C T I O N
Infection is the second leading cause of death in patients with chronic kidney disease (CKD) [1, 2] . One potential reason for the heightened infection risk is a high prevalence of vitamin D deficiency {both the major circulating metabolite, 25-hydroxyvitamin D [25(OH)D] and activated vitamin D (1,25-dihydroxyvitamin D)} among patients with CKD, particularly in those receiving chronic dialysis, owing to dietary restrictions and deficient renal 1a-hydroxylase activity [3] . Vitamin D may play an important protective role against pathogens, given that 25(OH)D supports the induction of antimicrobial peptides in response to both viral and bacterial stimuli [4] . Moreover, vitamin D metabolites have also been reported to induce innate antimicrobial effects, including induction of autophagy and synthesis of both reactive nitrogen intermediates and reactive oxygen intermediates [5] .
In the general population, studies have shown that higher levels of 25(OH)D or the use of vitamin D supplements is associated with a lower risk of infection [6, 7] . However, observational studies have shown conflicting evidence of this association in dialysis populations [8] [9] [10] [11] [12] [13] [14] [15] . Although several systematic reviews have been performed to investigate the healthrelated outcomes of vitamin D, such as all-cause mortality, cardiovascular disease and fractures in dialysis patients [16] [17] [18] [19] [20] [21] , none of these has focused on the relationship between vitamin D status or treatment and infection in this population.
Therefore we performed a systematic review to explore the association between circulating vitamin D concentrations and the risk of infection [any infection, infection-related hospitalization (IRH) or infection-related death] in patients with endstage kidney disease (ESKD) treated with chronic dialysis. We also explored whether the use of vitamin D supplements or vitamin D receptor activators (VDRAs) affected these outcomes.
M A T E R I A L S A N D M E T H O D S
The methods were pre-specifed in a protocol that was registered with the PROSPERO International Prospective Register of Systematic Reviews (Supplementary data, Item 1; http://www. crd.york.ac.uk/PROSPERO/display_record.php? ID¼CRD4201 8084779).
Our systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines [22] .
Search strategy
We performed a systematic literature search to identify all studies evaluating vitamin D status or supplementation of vitamin D or VDRA in relation to infection-related outcomes (any infection, IRH or infection-related death) among patients undergoing dialysis treatment. The search terms included the relevant key terms: 'vitamin D' and 'dialysis' and 'infection' (Supplementary data, Item 2). The search was conducted by two independent researchers (Z.L. and X.Q.) using the Cochrane Central Register of Controlled Trials  (CENTRAL, Issue 
Inclusion and exclusion criteria
Studies were included if they met the following criteria: (i) intervention studies [non-randomized intervention study or randomized controlled trial (RCT)], cohort study or casecontrol study; (ii) adult ESKD patients (age !18 years) undergoing haemodialysis (HD) or peritoneal dialysis (PD); (iii) reported at least one outcome of interest: risk of any infection, risk of IRH, infection-related mortality; (iv) presented data for different levels of serum 25(OH)D (the major circulating vitamin D metabolite) or (v) for medication studies, the intervention group received either nutritional vitamin D (D2/ergocalciferol and/or D3/cholecalciferol) supplements or a VDRA (paricalcitol, doxercalciferol, calcitriol, alfacalcidol, maxacalcitol and falecalcitriol) while the comparison group received placebo or no treatment. We excluded case reports, case series, editorials and review articles. Since the aim of this analysis was to compare outcomes for patients with high/normal versus low serum 25(OH)D levels, we also excluded studies that solely reported serum 25(OH)D as a continuous variable if original individual data were not accessible to permit categorization of serum 25(OH)D levels. There was no restriction of language or publication year. There was no restriction of sex or duration of follow-up time. In the case of multiple publications covering the same study population, we only included the report with the longer follow-up.
Exposure
The threshold for defining high/normal serum vitamin D levels, the type of vitamin D used (nutrient or activated form), dose and mode of delivery (oral or intravenous) varied among studies. In order to maximize the total study population, we included all formulations, regimens, vitamin D thresholds and dosing schedules.
Outcomes of interest
The primary outcome was the composite relative risk (RR) of any infection (any non-hospitalized fatal infection, IRH or infection-related death). All infections were included regardless of their source (community-acquired infections or health careassociated infections) or site (respiratory tract infection, genitourinary infections, bloodstream infections or sepsis, abdominal infections, skin and soft tissue infections, cardiovascular infections, musculoskeletal infections, nervous system infections and device-or dialysis-related infections). The secondary outcomes included the RR of each of these individual infection-related outcomes.
Study selection and data extraction
All the systematic search records from different databases were imported in ENDNOTE. After deduplication, eligible studies were listed and assessed independently by two reviewers (X.Q. and Z.L.) using pre-defined inclusion criteria. First, we excluded studies based on their titles and abstracts. Second, we excluded studies based on the inclusion criteria and listed the reasons for exclusion. Two authors (G.S. and Z.L.) used pre-defined forms to extract data from the studies, including information on region, study design, participants, concentration or level used as a cut-point to define vitamin D deficiency, the test methods, intervention details (types of vitamin D, modes of administration, dose, frequency and duration if applicable), comparison, outcomes, covariates, results and follow-up period. For each study, unadjusted RRs, odds ratios (ORs), hazard ratios (HRs) and incidence rate ratios were extracted, as well as risk assessments based on the most fully adjusted models. If different level groups [e.g. tertiles of 25(OH)D] were reported, the most extreme comparison, that is, the lowest versus highest level, was considered for the primary results. If the RR was not available in the studies, the numbers or incidences of the outcomes were extracted to calculate the RRs.
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Quality assessment
Two review authors (X. Q. and Z.L.) independently assessed the risk of bias of each included RCT using the Cochrane Collaboration's tool to assess sequence generation; allocation concealment; blinding of participants, staff and outcome assessors; completeness of outcome data and evidence of selective outcome reporting and other potential threats to validity. Risk of bias in cohort and case-control studies were assessed using the Newcastle-Ottawa Scale (NOS) tool [23] : selection of study participants (scores 0-4), comparability of subjects (scores 0-2) and exposure or outcome (scores 0-3), with the total score ranging from 0 to 9 (quality of study: low < 4; moderate !4-<7; high !7-<8). In the case of any disagreement, a third author (N.B.) also assessed the study.
Statistical analyses
For each outcome measure of interest, random effects metaanalysis was conducted to pool RRs for the dichotomous composite outcome (any non-hospitalized fatal infection, IRH, infection-related mortality) in order to determine the effect of different levels of 25(OH)D (high/normal versus low) or according to the use of vitamin D versus placebo/no use.
HRs and RRs were considered interchangeable in the analyses. If studies only reported ORs, these were converted into RRs using the formula RR ¼ OR/[(1 À P 0 ) þ (P 0 * OR)], in which P 0 was the event incidence in the control group [24] . This formula had a limitation of underestimating the variance of the RRs derived from the ORs [25] . Thus we performed a sensitivity analysis that excluded the studies with this transformation. I 2 was used to measure heterogeneity across studies, which was categorized as low (0-50%), moderate (51-75%) or high (>75%). Heterogeneity was explored through subgroup analyses whereby results were stratified by the type of vitamin D (VDRA and vitamin D supplement), administration of vitamin D (oral, intravenous or mixed), type of dialysis therapy (HD or PD), different outcomes (risk of any infection, IRH or infection-related mortality) and study design. We performed additional empirical Bayes meta-regression models in studies addressing the use of vitamin D as the exposure. These included the type of dialysis therapy (HD or PD), type of administration (oral or intravenous) and study sample size (<500 or !500 participants).
The presence of small study effects and publication bias was evaluated by funnel plots and Egger regression asymmetry analysis [26] . All data analyses were performed using Stata 14.0 (StataCorp, College Station, TX, USA).
R E S U L T S
Study selection
We identified 2158 records in English databases, 250 records in Chinese databases and 32 records from additional sources. Of these, 2140 records remained after removing duplicates. We excluded 2063 records based on titles and abstracts screening. Of the remaining 77 articles, we excluded 60 articles that did not meet inclusion criteria after full-text screening (21 articles not including dialysis patients; 35
articles without infection-related data; 1 article restricted to children; 3 articles [27] [28] [29] [8] [9] [10] [30] [31] [32] [33] [34] [35] [36] [37] and 6 for different levels of 25(OH)D [11-13, 15, 38, 39] } met the eligibility criteria and were considered for meta-analysis ( Figure 1 ).
Study characteristics
The six studies [11-13, 15, 38, 39] selected for evaluation of different serum levels of 25(OH)D enrolled a total of 5714 participants (Table 1) and were cohort studies. Three studies [12, 13, 15] provided data on infection-related death including 5220 HD patients. The remaining three studies [11, 38, 39] provided data for PD-related peritonitis enrolling 494 PD patients. The HD studies were from the Hemodialysis (HEMO) Study [13] , an international multicentre study that examined whether augmented dialytic urea removal or the use of high-flux dialysis could improve outcomes in HD patients (n ¼ 1) and patients from Germany [12, 15] (n ¼ 2) and China [11, 38, 39] (n ¼ 3). The mean age ranged from 48 to 71 years and the proportion of men ranged from 27.5% to 63.9%. The duration of follow-up varied between 6 months and 4 years. Categorization of low serum 25(OH)D levels varied among the six studies from <5.4 to <15 ng/mL. The most common testing method was enzymelinked immunosorbent assay (ELISA).
The 11 studies [8] [9] [10] [30] [31] [32] [33] [34] [35] [36] [37] assessing the use of vitamin D included a total of 92 309 patients (Table 2) . Among these studies, two [32, 33] evaluated nutritional vitamin D supplementation (both RCTs) and nine evaluated VDRA (seven observational cohort studies [8, 9, 30, 31, [35] [36] [37] and two casecontrol studies [10, 34] ). Four studies [30, 31, 36, 37] provided data for infection-related mortality and included 78 981 patients. Three studies [9, 10, 32] provided data for IRH and included 12 315 patients. The remaining studies provided data for infections, all types of infection [33] , PD-related peritonitis [8, 35] and herpes zoster [34] . These studies were from the USA [32, 33, 37] (n ¼ 3), Japan [9, 30, 31] (n ¼ 3), Latin America [36] (n ¼ 1), Austria [8, 35] (n ¼ 2), Canada [10] (n ¼ 1) and Taiwan [34] (n ¼ 1). The mean age ranged from 48 to 70 years and the proportion of men ranged from 52% to 84%. The duration of follow-up varied between 16 weeks and 5 years. Among those using VDRA, six [8] [9] [10] [34] [35] [36] used oral formulations, one [37] used an intravenous formulation and two [30, 31] used mixed formulations.
Risk of bias assessment
In general, the quality of the included observational studies was moderate according to the NOS criteria (4 studies with moderate quality and 11 studies with high quality). The common item underscored in this scale was an unclear definition of the outcomes of infection, which might have been related to the fact that infection was usually not the primary outcome. One RCT [32] provided only its primary outcome (the change in epoetin dose of >6 months) in the protocol. Since they did not mention infection as an outcome in the study protocol, this raised the possibility of selective outcome reporting. Another RCT [33] had an imbalance in missing data between groups, thereby implicating a high risk of incomplete outcomes.
The full quality assessment is detailed in Supplementary data, Tables S1-S3.
Effects of 25(OH)D on infection-related outcomes
When compared with individuals with low serum levels of 25(OH)D, the pooled adjusted risk for composite infection was 39% lower [RR 0.61 (95% CI 0.41-0.89), all were cohort studies] in those with high/normal levels, with moderate heterogeneity (I 2 ¼ 60.5%, P ¼ 0.03; Figure 2 ). In patients undergoing PD, the risk of PD-related infections was 66% lower [RR 0.34 (95% CI 0.20-0.58)] in those with high/normal levels of 25(OH)D than in those with low levels of 25(OH)D, with minimal heterogeneity (I 2 ¼ 0%, P ¼ 0.71; Supplementary data, Figure S1 ). In patients undergoing HD, the risk of infection-related mortality was 12% lower [RR 0.88 (95% CI 0.70-1.08)] in those with high/normal levels of 25(OH)D than in those with a low level, with minimal heterogeneity (I 2 ¼ 0%, P ¼ 0.43; Supplementary data Figure 1S ).
Effects of vitamin D use on infection-related outcomes
The pooled adjusted risk for infection-related outcomes was Chao et al. Vitamin D and infections in ESRD all were observational studies; Figure 3] , with high heterogeneity (I 2 ¼ 92.6%, P < 0.001; Figure 3 ). When compared with those who did not use VDRA, the pooled adjusted risks for composite infection-related outcomes were 46% and 61% lower in those taking oral [RR 0.53 (95% CI 0.35-0.82), all were observational studies] and intravenous [RR 0.39 (95% CI 0.31-0.48)] VDRA, respectively (Supplementary data, Figure S2) . A lower risk of infection-related mortality and a lower risk of infection were observed in those who used VDRA (Supplementary data, Figure S3 ).
Meta-regression and sensitivity analyses
A sensitivity analysis examining VDRA use included seven cohort studies and demonstrated a similar association between the use of VDRA and a lower risk of infection-related outcomes (Supplementary data, Figure S4 ). Meta-regression analyses suggested that PD patients in studies with a larger sample size and using intravenous VDRA showed lower RRs when compared with their counterparts (Table 3) .
Publication bias
Publication bias was indicated in included studies investigating the level of 25(OH)D (P ¼ 0.007 in Egger's test; Supplementary data, Figure S5 ) but not the use of vitamin D (P ¼ 0.12 in Egger's test; Supplementary data, Figure S6 ).
D I S C U S S I O N
This meta-analysis, based on 17 studies of patients receiving long-term dialysis, showed that the risk of infection-related outcomes was lower in patients with higher serum levels of 25(OH)D. Furthermore, the use of vitamin D, particularly VDRA, was also associated with a lower risk of infectionrelated outcomes in this population.
Our observations are in line with the evidence from general population studies, suggesting an independent association between low serum concentrations of 25(OH)D and susceptibility to infection, as well as a potentially protective effect of vitamin D against infections [7, 40] . In contrast, previous systematic reviews of either vitamin D status or use of vitamin D treatment in dialysis populations have not focused on infection-related outcomes but have instead focused on all-cause mortality [20] in relation to vitamin D status or all-cause mortality [17, 18, 21] , cardiovascular outcomes (CVD-related mortality [17, 18, 21] , vascular calcification [17] ), bone-related outcomes (fracture [17] , bone pain [17] , bone histomorphometry [17] ) and laboratory-related outcomes {parathyroid hormone (PTH) [17, 19] , serum phosphorus [17, 19] , serum calcium [17, 19] and serum alkaline phosphatase [17] } in relation to the use of vitamin D (supplementation or VDRA).
Vitamin D has been shown to play an important role in maintaining normal immune function and crosstalk between the innate and adaptive immune systems, which are essential in infection prevention [41] . In innate immunity, vitamin D promotes the production of cathelicidin and b-defensin 2, enhances the capacity for autophagy via toll-like receptor activation and influences complement concentrations [42] . In adaptive immunity, vitamin D suppresses the maturation of dendritic cells and weakens antigen presentation [41] . These pathways provide a biologically plausible mechanism underpinning the observed association between higher serum 25(OH)D levels or the use of vitamin D with a lower risk of infection. This association is consistent in PD patients but not in HD patients. It should be noted that studies in PD patients only evaluated PDrelated peritonitis, not other infections, while HD studies explored all types of infection-related outcomes. It remains a question whether specific mechanisms of vitamin D action may differ between different dialysis populations. We found that VDRA but not nutritional supplements were associated with a lower risk of infection. This discrepancy might be related to differences in power (only two studies of nutritional vitamin D supplements) or outcome ascertainment (infection was not the primary outcome). It is still unclear whether nutritional vitamin D supplementation has an effect on infections. Other RCTs in non-dialysis populations report inconsistent findings [14, 43] . [45, 46] , it is also conceivable that nutritional vitamin D supplements may exert less of an effect on infections than VDRA, owing to reduced delivery of 25(OH)D to the renal proximal tubule and subsequent decreased 1a-hydroxylation in the setting of reduced glomerular filtration rate in dialysis patients [42] .
The Kidney Disease: Improving Global Outcomes CKDmineral and bone disorder (CKD-MBD) guidelines currently only advocate the use of vitamin D to treat CKD-MBD when intact PTH levels exceed nine times the upper normal limit and do not consider infection-related outcomes [47] . Similarly, the International Society for Peritoneal Dialysis guidelines cite the We also acknowledge a number of limitations that need to be considered when interpreting our findings:
1. Our analysis plan selected the most adjusted RR presented in the studies, which may have resulted in outcome reporting bias despite representing the most conservative risk estimation. 2. Considering that our meta-analysis was mostly based on observational studies, except for two RCTs exploring nutritional vitamin D supplementation, our data cannot prove causality and residual or unmeasured confounding could not be eliminated. 3. We found overall high heterogeneity in our estimates.
Heterogeneity may be attributed in part to the different study designs and differences with regard to patient characteristics (e.g. diabetes prevalence, mean dialysis vintages, sex distribution, mean age and mode of dialysis), intervention type (nutrient supplementation or VDRA), 25(OH)D measurement method and concentration of vitamin D levels to define deficiency, different follow-up periods, study quality and sample size. However, we were unable to perform all of these subgroup analyses owing to the limited data available and lack of access to the original, individual patient data. 4. Although the tests for publication bias were insignificant, the possibility of publication bias could not be confidently excluded.
In conclusion, lower serum levels of 25(OH)D and the use of vitamin D, particularly VDRA, were each associated with a FIGURE 2: Forest plot depicting the meta-association between high/normal versus low level of 25(OH)D and risk for infection-related outcomes using the DerSimonian and Laird random effects model. All the included studies were cohort studies.
Vitamin D and infections in ESRD lower risk of composite infection in patients with ESKD receiving chronic dialysis. An adequately powered RCT examining the effect of vitamin D supplements on infection-related outcomes in such patients is both important and justified.
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